BIND-014 (docetaxel nanoparticles for injectable suspension)

DRUG2 trials

Sponsors

BIND Therapeutics

Conditions

Cervical CancerCholangiocarcinomaKRAS Positive Patients With Non-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckSquamous Cell Non-small Cell Lung CancerUrothelial Carcinoma

Phase 2

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

CompletedNCT02283320

BIND TherapeuticsKRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer

Start: 2014-09-30End: 2016-04-30Updated: 2016-04-18

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

TerminatedNCT02479178

BIND TherapeuticsCervical Cancer, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck +1

Start: 2015-06-30End: 2020-01-31Updated: 2016-04-14